Cigna Group
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.62B | $39.68B | $37.88B | $34.91B | $32.38B | $29.12B | $21.99B | $21.25B |
| Pharmacy Revenues | $4.50B | $4.19B | $3.72B | $3.37B | $3.18B | $3.00B | $2.06B | $2.13B |
| Premiums | $31.35B | $30.14B | $29.11B | $26.80B | $24.67B | $21.99B | $16.37B | $15.63B |
| Fees and Other Revenues | $4.37B | $4.06B | $3.75B | $3.46B | $3.25B | $2.91B | $2.34B | $2.30B |
| Net Investment Income | $1.28B | $1.22B | $1.18B | $1.18B | $1.15B | $1.14B | $1.14B | $1.15B |
| Realized Investment Gains (Losses) | $112.0M | $79.0M | $116.0M | $112.0M | $129.0M | $93.0M | $81.0M | $43.0M |
| Cost of Revenue | $2.46B | $2.47B | — | — | — | — | — | — |
| Gross Profit | $39.16B | $37.21B | — | — | — | — | — | — |
| Gross Margin | 94.1% | 93.8% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $10.03B | $9.79B | — | — | — | — | — | — |
| Operating Income | $3.94B | $3.09B | — | — | — | — | — | — |
| Operating Margin | 9.5% | 7.8% | — | — | — | — | — | — |
| Interest Expense | $243.0M | $251.0M | — | — | — | — | — | — |
| Pretax Income | $3.61B | $2.98B | — | — | — | — | — | — |
| Income Tax Expense | $1.37B | $1.14B | — | — | — | — | — | — |
| Net Income | $2.23B | $1.84B | — | — | — | — | — | — |
| Net Margin | 5.4% | 4.6% | — | — | — | — | — | — |
| EPS (Basic) | $8.92 | $7.31 | — | — | — | — | — | — |
| EPS (Diluted) | $8.77 | $7.19 | — | — | — | — | — | — |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | 255.1M | 259.6M | — | — | — | — | — | — |
| Dividends Per Share | $0.04 | — | — | — | — | — | — | — |